December 7, 2016Current Pharmaceutical Design
The Role of Antiplatelet Therapy in Primary Prevention. A Review
Why the study?
Does antiplatelet therapy (primarily aspirin) reduce cardiovascular events in individuals without established cardiovascular disease?
Population
Individuals without established cardiovascular disease
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Antiplatelet primary prevention balances modest efficacy against bleeding risk; leaves open individualized selection in low-risk patients.
Structured PICO
Does antiplatelet therapy (primarily aspirin) reduce cardiovascular events in individuals without established cardiovascular disease?
P
Population
Individuals without established cardiovascular disease
I
Intervention
Antiplatelet therapy (primarily aspirin)
O
Outcome
Non-fatal myocardial infarction, cardiovascular death, and bleedinghard clinical
Aspirin for primary prevention of cardiovascular disease reduces non-fatal myocardial infarction but consistently increases bleeding risk, necessitating careful patient selection.
Cite This Study
Østergaard et al. (2016) studied this question.